What is AFFiRiS?
AFFiRiS is a clinical-stage biopharmaceutical firm specializing in the development of innovative immunotherapies for chronic diseases, with a particular focus on neurodegenerative conditions and hypercholesterolemia. The company leverages its proprietary AFFITOME technology to engineer Specific Active Immunotherapies (SAIT), designed to harness the immune system to combat disease progression. This approach aims to address critical unmet medical needs by offering more effective treatment options that potentially reduce dosing frequency and improve patient quality of life.
How much funding has AFFiRiS raised?
AFFiRiS has raised a total of $66.1M across 4 funding rounds:
Other Financing Round
$33.9M
Private Equity
$11.3M
Other Financing Round
$10M
Other Financing Round
$10.9M
Other Financing Round (2011): $33.9M with participation from MIG Capital
Private Equity (2016): $11.3M, investors not publicly disclosed
Other Financing Round (2016): $10M supported by MIG Capital, Santo Holding, and FCPG Affi
Other Financing Round (2017): $10.9M featuring MIG Capital
Key Investors in AFFiRiS
MIG Capital
MIG Capital is a Munich-based venture capital firm that primarily invests in innovative ideas across Europe, focusing on startups in the Life Sciences and Deep Tech sectors. The company aims to overcome boundaries and improve the world, placing founders at the center of their efforts. Unique in the market, MIG Capital is the only retail venture capital investor in Germany, with funds that are publicly accessible and fully supported by private investors. With a portfolio that includes active investments and successful exits, MIG Capital is committed to fostering the companies of tomorrow.
Santo Holding
Undisclosed investor participating in the funding round.
FCPG Affi
Undisclosed investor participating in the funding round.
What's next for AFFiRiS?
The substantial enterprise-level funding and recent strategic investment indicate a pivotal phase for AFFiRiS. This capital infusion is expected to accelerate the clinical development of its SAIT pipeline, potentially enabling further trials and regulatory submissions. The company's focus on neurodegenerative diseases and hypercholesterolemia positions it within high-impact therapeutic areas, suggesting a strategic push towards commercialization and market entry. Future growth will likely involve expanding its research and development capabilities and forging strategic partnerships to enhance its market reach.
See full AFFiRiS company page
